TYRP1 and neoplasm: In a mouse melanoma model treated with cyclophosphamide and an antibody against tyrosinase-related protein 1 (aTRP1), the combination group exhibited significantly better control of tumor progression compared to the control group, as a result of the accumulation of intra-tumor macrophages promoted by CD90+NK1.1− ILC3s [293].